Pancreatic Cancer

Completion of Clinical Trial Enrollment Announced

Published in Cancer Weekly, March 23rd, 1998

Imutec Pharma Inc., Toronto, Ontario, Canada, announced that it has completed patient enrollment for its Phase I/II pancreatic cancer trial at the Rush Presbyterian St. Luke's Medical Center in Chicago, Illinois.

The completion of this Phase I/II trial marks the achievement of an other significant milestone by Imutec Pharma. The results of this trial aids in discussions with potential partners regarding the licensing of marketing and distribution rights for Virulizin, which is in line with the company's business strategy of out-licensing products prior to Phase III clinical trials.

"I am pleased to report that enrollment of our current trial is now...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (1998-03-23)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry